|Videos|January 20, 2021
Ovarian Cancer: FDA Approved PARP Inhibitors
Author(s)Thomas Herzog, MD
Advertisement
Episodes in this series
Advertisement
Related to this article
New analyses from the RAMP 201 trial demonstrated responses in KRAS wild-type recurrent LGSOC with avutometinib plus defactinib.
Data from RAINFOL-01 showed rinatabart sesutecan achieved responses in heavily pretreated platinum-resistant ovarian cancer with low or no FRα expression.
Initial phase 1/2 data showed a 73% objective response rate with ubamatamab in 11 patients with heavily pretreated low-grade serous ovarian cancer.
Advertisement
Advertisement
Trending on CancerNetwork
1
Reading a Changed Eye Examination and Impact on Therapy
2
FDA Expands Approval for Nogapendekin Alfa in BCG-Unresponsive NMIBC
3
VS-7375 Yields Responses in KRAS G12D–Mutated Solid Tumors
4
Operationalizing the First Dose and Building the Oncology and Eye Care Partnership
5